Don’t Jump to Suzetrigine for Acute Pain

March 2025

The spotlight is on suzetrigine (Journavx), the first med in a new class of NON-opioid analgesics for acute pain in over 2 decades.

Suzetrigine is a selective sodium channel blocker...that prevents pain signals in the peripheral nervous system from reaching the brain.

It’s NOT a controlled substance...and it doesn’t have warnings about misuse, respiratory depression, etc.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote